ArticleJournal of the Society for Cardiovascular Angiography & Interventions2026
Ventricular Migration of Transcatheter Valve During Transcatheter Aortic Valve Replacement After Valve-Sparing Root Replacement: A Case Report.
Article in Journal of the Society for Cardiovascular Angiography & Interventions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcatheter aortic valve replacement is increasingly used off-label for native aortic regurgitation in high surgical risk patients, although the absence of annular calcification-particularly after prior valve-sparing aortic root replacement-complicates valve anchoring and increases migration risk. We report a 66-year-old man with severe symptomatic aortic regurgitation after valve-sparing aortic root replacement and hemiarch repair who underwent transcatheter aortic valve replacement. Following deployment of a 29-mm Evolut FX+ valve (Medtronic), valve migration into the left ventricular outflow tract caused severe regurgitation and instability. A second 26-mm SAPIEN 3 Ultra valve (Edwards Lifesciences) was successfully implanted to stabilize the prosthesis, restoring competence and enabling uneventful recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.